Current management of parainfluenza pneumonitis in immunocompromised patients: a review

Ann R Falsey
University of Rochester, Rochester General Hospital, Rochester, NY, USA

Abstract: Parainfluenza viruses (PIV) are common respiratory viruses that belong to the Paramyxoviridae family. PIV infection can lead to a wide variety of clinical syndromes ranging from mild upper respiratory illness (URI) to severe pneumonia. Severe disease can be seen in elderly or chronically ill persons and may be fatal in persons with compromised immune systems, particularly children with severe combined immunodeficiency disease syndrome and hematopathic stem cell transplant recipients. At present, there are no licensed antiviral agents for the treatment of PIV infection. Aerosolized or systemic ribavirin in combination with intravenous gamma globulin has been reported in small, uncontrolled series and case reports of immunocompromised patients. A number of agents show antiviral activity in vitro and in animals, but none are currently approved for human use.

Keywords: parainfluenza virus, antiviral agents, immunocompromised host

Introduction
Parainfluenza viruses (PIV) are common respiratory viruses that belong to the Paramyxoviridae family and include four serotypes and two subtypes (1, 2, 3, 4a, and 4b).1 PIV infection leads to a wide variety of clinical syndromes ranging from mild upper respiratory illness (URI) to severe pneumonia.2 PIV-1 tends to cause biennial fall epidemics and accounts for approximately 30%–50% of cases of croup in young children.3 PIV-2 is not as common as other serotypes and may cause alternating outbreaks with PIV-1, and most children are infected between the ages of 2 and 5 years. PIV-3 affects younger children and is second only to respiratory syncytial virus (RSV) as a cause of bronchiolitis and pneumonia in children less than 6 months old.2 It is estimated that 12% of hospitalizations for lower respiratory tract infection (LRTI) in children are due to PIV. PIV-4 affects older children and is the least common serotype. Because immunity is incomplete, reinfections occur throughout life and are generally mild, self-limited illnesses in young healthy adults. Severe disease can be seen in elderly or chronically ill persons and can be fatal in persons with compromised immune systems.1 Severe giant cell pneumonia has been reported in children with severe combined immunodeficiency disease syndrome (SCIDS), solid organ, and hematopathic stem cell transplant (HSCT) recipients.4,6 This review will focus on PIV infection in immunocompromised patients, the antiviral therapy in development, and current management of PIV in this patient population.
Virology

The parainfluenza viruses are enveloped negative sense RNA viruses. The genome, unlike influenza, is nonsegmented, ∼15,000 nucleotides in length, and encodes six structural proteins. The virus has two membrane proteins, the hemagglutinin neuraminidase (HN) and the fusion protein (F) (Figure 1). HN recognizes sialic acid-containing glycolipids and glycoproteins of the target host cell and allows binding. HN receptor interaction is needed for F protein triggering and after fusion with the cell membrane; the virus is uncoated and released into the cytoplasm (Figure 2). After early events, primary transcription occurs, antigenome RNA is synthesized, the virus is assembled, and finally the new virus buds and is released. HN also acts as a sialidase to remove sialic acid from the virus particles and prevent self-aggregation. Recent elucidation of protein structure and functions has furthered the development of new antiviral agents for the treatment of PIV infection.

Immunology

Host defense against PIV is mediated by humoral and cellular immunity. Antibodies to the two surface glycoproteins, F and HN, are neutralizing and antibodies to either protein can protect against PIV challenge. Secretory IgA develops after natural infection and has been shown to neutralize virus and ameliorate disease. Cytotoxic T lymphocyte responses appear to play a role in the clearance of the virus from the lower airways in hamster and mouse models of PIV infection. T cell epitopes have been demonstrated on the HN, P, and NP proteins of PIV.

PIV infection in immunocompromised hosts

The devastating effects of PIV infection in immunocompromised persons were first recognized in children with SCIDS, where giant cell pneumonia has been demonstrated at autopsy. This rare genetic disorder is characterized by primary deficiency of T, B, and NK cell-mediated immunity that predispose afflicted patients to serious infections, including respiratory viruses. Persistent respiratory tract infection and shedding has been observed in SCID and HIV patients. The natural history of PIV infection in HIV patients is not well defined, but severe illness appears uncommon unless significant T cell dysfunction has occurred. Severe PIV infection has also been observed in patients with hematologic malignancies undergoing chemotherapy. High rates of pneumonia (55%) and death (27%) have been noted, with low lymphocyte counts and the presence of pneumonia independently associated with risk of death. The largest immunocompromised patient populations affected by PIV infection are solid organ and HSCT recipients. The first report describing the clinical features and outcomes of PIV infection in solid organ transplant patients was in 1979 and involved 16 kidney transplant recipients. Although no deaths occurred, an increased rate of acute graft rejection was noted. Among heart and lung transplant patients with PIV infection, 82% developed acute allograft rejection and 32% developed bronchiolitis obliterans. Using culture direct immunofluorescence testing, PIV infection rates range from 2.2% to 14% among pediatric and adult HSCT transplant patients. More recently, higher rates of infection and asymptomatic shedding have been observed using new sensitive molecular diagnostic tests. Most infections begin with typical URI symptoms and low-grade fever. Sinusitis may be seen on imaging studies in approximately 40% of patients. Progression from URI to lower tract disease is common with rates ranging from 18% to 77%. Risk of progression is associated with steroid use and lymphopenia and may be less with nonmyeloablative conditioning. Radiographic findings can be variable with focal or diffuse interstitial and alveolar interstitial infiltrates described. Risk of death once pneumonia has developed can be very high ranging from 25% to 45%. Extra pulmonary manifestations may also occur with parotitis, and dissemination to the brain, myocardium, and pericardium have been
described. Survival from acute PIV infection has been associated with significant declines in lung function at 1 year post transplant. Interestingly, in one study of HSCT patients, decline in airflow in PIV-infected patients was noted even among patients with URI symptoms alone.

Therapy
Presently there are no licensed antiviral agents for the treatment of PIV infection. Treatment is primarily symptomatic; aerosolized or systemic ribavirin in combination with intravenous gamma globulin has been reported in small, uncontrolled series, and case reports. A number of agents show antiviral activity in vitro and in animals.

Ribavirin
Ribavirin is a nucleoside analogue that has broad activity in vitro against many RNA and DNA viruses. Aerosolized ribavirin is currently licensed for the treatment of severe RSV in young children and oral an intravenous ribavirin has been used for the treatment of other viral infections such as hepatitis C and Lassa fever. Aerosolized ribavirin is generally well tolerated with mild skin and conjunctival irritation reported, although increased cough and bronchospasm may occur. In addition, teratogenicity in rodents has been reported and therefore it is recommended that pregnant health care workers avoid exposure. Systemic ribavirin can be associated with a reversible hemolytic anemia. A number of mechanisms have been proposed for the antiviral effect of ribavirin and include: decreased guanosine-5'-triphosphate (GTP) pools; inhibition of genomic RNA capping; direct inhibition of viral encoded polymerases; and increased mutation leading to error catastrophes and an immunomodulatory effect. Ribavirin appears to polarize the human T cell response towards a type 1 cytokine profile mediated by interleukin-2, INF-γ, and TNF-α.

Unfortunately, most of the information regarding the clinical utility of ribavirin comes from case reports or small, uncontrolled series. In children with SCIDS and PIV infection, aerosolized ribavirin has been administered over long periods of time (3–10 months) without apparent toxicity. Although ribavirin has been well tolerated, the efficacy for the treatment of PIV infection is difficult to determine, as most case series involve small numbers, different routes of administration, combination treatment with intravenous gamma globulin (IVIG), and different patient populations. The majority of data are in HSCT patients and consensus indicates that ribavirin is not effective for PIV...
pneumonia when given late in the course of illness, especially if respiratory failure has ensued.17,22,27 Some reports suggest a modest benefit if the drug is given at the early stage of upper respiratory tract involvement, but this is controversial because of the lack of controlled trials. Most of the studies of HSCT patients report ribavirin treatment of both URI and LRTI PIV infection and demonstrate no clear benefit of ribavirin treatment (Table 1). Wendt et al reported PIV infection in 12 adults and 15 children undergoing HSCT.27 Seventy percent had lower respiratory tract involvement and of those, 32% developed respiratory failure. Nine subjects received inhaled ribavirin with a survival rate of 78%, which was the same as those who were not treated. Notably, treatment was started late in the course of symptoms, on average after 11 days of illness. Nichols et al reported the treatment and outcomes of 253 HSCT patients with PIV infection;22 13% had LRTI at presentation and another 13% progressed from URI to pneumonia. The use of ribavirin with or without IVIG was assessed in patients with LRTI and had no effect on 30-day mortality, and the risk of death was highest in patients with bacterial or fungal copathogens (Figure 3).

Although the efficacy of ribavirin for the treatment of LRTI is debatable, early treatment to prevent progression to pneumonia remains an unanswered question. In addition, the role of ribavirin to prevent long-term pulmonary sequelae deserves further exploration since significant airflow decline after PIV infection has been shown in both HSCT and heart and lung transplant recipients.20,33 In a small cohort of heart-lung transplant patients with PIV infection, the use of IVIG, steroids, and ribavirin was associated with a slower decline in lung function compared to historical controls.3

**Other antiviral agents**

A number of chemical compounds have shown in vitro activity against PIV and include: protein synthesis inhibitors (puromycin); benzothiazole derivative; 1, 2, 4-thiadiazol-2 ylenanamide; carbocyclic-3-deezaadenosine; ascorbic acid; calcium elenolate; and extracts of *Sanicula europaea* leaves. However, none of these agents have clinical applications.3 Amantadine shows activity against PIV in high concentration in vitro, but does not decrease URI symptoms in PIV challenged adults.1

Recent work has focused on transcription inhibitors, and Mao et al have demonstrated novel small molecules (C5 and C7) with potent anti-PIV activity.9,39 The C protein of PIV is a multifactorial accessory protein that inhibits viral transcription and interferon signaling. Removal of the N-terminal 25 amino acids of the C-protein potentiates the inhibitory activity of the protein and shows promise as a PIV antiviral agent.39

Another approach has been to target the binding or neuraminidase function of the HN protein. The HN protein recognizes sialic acid-containing glycolipids and glycoproteins on the host target cells and allows binding to occur. It also acts as a sialidase to remove sialic acid from the virus particles to prevent self-aggregation, and work is continuing to identify novel sialic acidase inhibitors.8 DAS181 is a novel inhaled recombinant sialidase fusion protein that interferes with the initial binding of HN with the target cell sialic acid-containing receptor. DAS181 contains the catalytic domain of actinomyces viscous sialidase and the heparin-binding domain of human amphiregulin to prolong DAS181 retention on the epithelial surface.7,40 The drug was developed as an antiviral agent for influenza.4 Since sialic acid residues serve as the cellular receptors for both influenza and PIV, DAS181 has been explored for PIV antiviral activity. Compassionate use of this agent was recently reported in a 63-year-old woman with acute myelogenous leukemia (AML) post HSCT, who developed PIV pneumonia.40 Administration of the inhaled product was associated with clinical improvement and decreased PIV shedding; however, symptoms and shedding recurred 2 weeks

### Table 1 Reports of ribavirin treatment of PIV infection in HSCT patients

<table>
<thead>
<tr>
<th>Year</th>
<th>Author (ref)</th>
<th>N of PIV cases</th>
<th>N of LRTI</th>
<th>Route of administration</th>
<th>N surviving/ N treated (%)</th>
<th>N surviving/ N not treated (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>Wendt et al27</td>
<td>27</td>
<td>19</td>
<td>Aer</td>
<td>7/9 (78)</td>
<td>14/18 (78)</td>
</tr>
<tr>
<td>1996</td>
<td>Lewis et al17</td>
<td>61</td>
<td>27</td>
<td>Aer</td>
<td>3/5 (60)</td>
<td>51/56 (91)</td>
</tr>
<tr>
<td>1997</td>
<td>Sparrell et al33</td>
<td>3</td>
<td>2</td>
<td>PO/IV</td>
<td>3/3 (100)</td>
<td>NA</td>
</tr>
<tr>
<td>2000</td>
<td>Chakrabarti et al34</td>
<td>5</td>
<td>4</td>
<td>Aer/PO/IV</td>
<td>5/5 (100)</td>
<td>NA</td>
</tr>
<tr>
<td>2001</td>
<td>Chakrabarti et al35</td>
<td>5</td>
<td>3</td>
<td>PO</td>
<td>4/5 (80)</td>
<td>NA</td>
</tr>
<tr>
<td>2001</td>
<td>Elizaga et al36</td>
<td>24</td>
<td>14</td>
<td>Aer/IV</td>
<td>12/18 (67)</td>
<td>4/6 (67)</td>
</tr>
<tr>
<td>2001</td>
<td>Lujan-Zilbermann et al37</td>
<td>12</td>
<td>7</td>
<td>Not specified</td>
<td>2/3 (67)</td>
<td>9/9 (100)</td>
</tr>
<tr>
<td>2001</td>
<td>Nichols et al38</td>
<td>253</td>
<td>55</td>
<td>Aer +/- IVIG</td>
<td>22/31 (72)</td>
<td>14/24 (58)</td>
</tr>
<tr>
<td>2006</td>
<td>Dignan et al39</td>
<td>24</td>
<td>12</td>
<td>Aer/IV</td>
<td>7/8 (88)</td>
<td>16/16 (100)</td>
</tr>
</tbody>
</table>

**Abbreviations:** PIV, parainfluenza virus; HSCT, hematopathic stem cell transplant; N, number; LRTI, lower respiratory tract infection; Aer, aerosolized; PO, oral; IV, intravenous; IVIG, intravenous gamma globulin; NA, not available.
after stopping treatment when she presented with relapsed AML. The drug was well tolerated without discernible toxicity and is a promising new therapy for PIV infection.

The discovery of the three-dimensional structure of the PIV HN has allowed the design of inhibitors that fit into the binding site of the globular head. HN receptor interaction is not only needed for binding to the target cell but is also needed for F protein triggering and fusion.7 Additional promising agents are HN inhibitors, BCX 2798, and BCX 2855, which bind to the conserved catalytic binding site of PIV.42,43 These agents effectively inhibit PIV growth in the mouse model and mice treated intranasally showed decreased PIV shedding and inflammatory histopathologic changes in the lungs.

The F protein mediates fusion of the virus and host cell and is another alternative antiviral target. Rho A, a small GTPase, facilitates syncytial formation.44 Pastev et al reported that a Rho A-derived peptide inhibited both RSV and PIV-3 in vitro by inhibiting cell-to-cell fusion in vivo by reducing the peak titer by 100-fold in RSV-infected mice.44 Synthetic peptides derived from heptad repeat domain of HIV gp41 have been shown to be potent inhibitors of HIV infection and fusion.45 Because fusogenic viruses, including PIV, demonstrate amino acid sequence homology at the amino termini with HIV, researchers have investigated the possibility of finding similar functional homologues for PIV.46 Lambert et al were successful at identifying such a peptide for PIV-3 that blocked PIV-mediated syncytia formation in cell culture.45

Immunomodulators and antibody therapy
Nonspecific immunostimulators have been explored as potential treatments for PIV infection including dihydroheptaprenol, imiquimod, and interferon (IFN) alpha and gamma.1 In vitro IFN inhibits viral transcription and has been shown to reduce PIV replication in A549 cells by 100-fold.46 Immunoglobulins have demonstrated some antiviral efficacy in the cotton rat model of PIV-3 infection.47 Using two lots of commercial, human-pooled IVIG to treat PIV-infected cotton rats, Ottolini et al demonstrated a significant decrease in lung PIV titers, although nasal titers were unchanged with treatment.47 In subsequent studies, the combination of steroids with IVIG produced the most favorable results.48,49 While the use of IVIG leads to improved viral clearance, there was no effect on inflammatory changes in the lungs and treatment with steroids alone lead to decreased lung pathology but a 10-fold increase in viral growth.49 The combination of IVIG and steroids demonstrated both favorable effects but rebound of pathology was observed if treatment was not continued for eight or more days.

Conclusion
PIV infection in immunocompromised patients is relatively common and can be associated with a spectrum of diseases, ranging from mild URI symptoms to severe respiratory failure and death. Risk of progression to pneumonia appears to be related to use of steroids and lymphopenia. Once pneumonia has developed, death rates are high and at the present time, effective antiviral therapy is not available. Randomized controlled trials of ribavirin to prevent progression of PIV from the upper to the lower respiratory tract are needed. New information on the structure and function of PIV proteins and the cellular processes of the PIV life cycle should provide new areas of research for antiviral agents.

Disclosure
Dr Falsey has consulted for Medimmune, AstraZeneca, Novartis, Novavax, GlaxoSmithKline, and Sanofi Pasteur. There was no conflict of interest for any of the materials presented in this manuscript.

References


